Research & Development
KT Tape introduces KT Recovery+ Wave
23 February 2021 -

KT Tape, a company that deals with drug-free pain relief, has launched its KT Recovery+ Wave, it was reported on Monday.

The company says that the product is a clinically proven and FDA approved wearable device that offers drug-free pain relief for sports injuries, knee pain, arthritis, back pain, carpal tunnel, sprains and more.

The new KT Recovery+ Wave utilises sensation-free electromagnetic pulses called pulsed shortwave therapy to decrease nerve hypersensitivity and relieve pain. It has a guaranteed battery life of 250 hours and is available at an MSRP of USD34.99.

Login
Username:

Password:


Related Headlines

Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

Sage Therapeutics, Biogen Post Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

InnoCare wins FDA's ODD for gunagrabtinib for treatment of cholangiocarcinoma

Attralus Presents Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting

Organicell Touts Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using Zofin

FDA Authorizes LetsGetChecked's Home Collection Coronavirus (COVID-19) Test For Use on Minors

Biodesix SARS CoV-2 Neutralization Antibody Test Now Commercial Available

Stratatech receives US FDA approval for StrataGraft

US FDA accepts for review Hugel America's LetibotulinumtoxinA Injection biologics License Application

Mallinckrodt wins FDA approval for StrataGraft to treat thermal burns containing intact dermal elements

Brazil's health regulator extends validity of J&J's COVID vaccine to 4.5 months

KVK-Tech and Penn Life Sciences name new chief operating officer

Ascentage Pharma's lisaftoclax Investigational New Drug application receives US FDA approval

Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TR

Adaptive Phage Therapeutics Forges Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases